Akebia Announces Participation in the Future Leaders in the Biotech Industry Conference
* Reuters is not responsible for the content in this press release.
CINCINNATI, OH, Apr 06 (MARKET WIRE) --
Akebia Therapeutics, Inc., a small molecule discovery and development
company focused on anemia and vascular disorders, today announced that
Joseph Gardner, Ph.D., president and chief executive officer will be
presenting at the BioCentury and Thomson Reuters Future Leaders in the
Biotech Industry Conference. During the presentation, Dr. Gardner will
provide an overview of the company including recent product development
activities and strategic advancements.
The following are specific details regarding Akebia's presentation at the
conference:
BioCentury & Thomson Reuters Future Leaders in the Biotech Industry
Conference
Date: April 8, 2010
Time: 10:00 AM
Location: Millennium Broadway Hotel & Conference Center, New York, NY
Room: Presentation Room 311 (Breakout in Room 310 immediately following)
About Akebia Therapeutics
Akebia Therapeutics is a discovery and
development company focused on anemia and vascular disorders. Akebia's
lead program, AKB-6548, an orally bioavailable HIF-prolyl hydroxylase
(HIF-PH) inhibitor for patients with anemia, is in phase 1 clinical
trials. AKB-6548 potentially promises to be a safer, less expensive,
orally dosed pharmaceutical to stimulate endogenous EPO production.
Additionally, Akebia has a novel HPTPbeta inhibitor / Angiopoietin 2
modulator, AKB-9778, for the treatment of vascular leak syndrome and
critical limb ischemia which is scheduled to commence phase 1 clinical
trials in 2010.
Website: www.akebia.com.
CONTACT:
Ian Howes, CFO & V.P. Corporate Development, Akebia Therapeutics, Inc.
513/985-1923, Email Contact
Michelle Linn, Linnden Communications, 508/362-3087, Email Contact
Copyright 2010, Market Wire, All rights reserved.
-0-
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters